Villere ST Denis J & Co. LLC lifted its holdings in Alpha Cognition Inc. (NASDAQ:ACOG - Free Report) by 201.0% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 71,778 shares of the company's stock after buying an additional 47,928 shares during the period. Villere ST Denis J & Co. LLC owned about 0.45% of Alpha Cognition worth $363,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also modified their holdings of the business. Solas Capital Management LLC purchased a new stake in shares of Alpha Cognition during the 4th quarter worth about $8,096,000. Sphera Funds Management LTD. bought a new stake in Alpha Cognition in the fourth quarter worth approximately $3,652,000. Alyeska Investment Group L.P. acquired a new position in shares of Alpha Cognition during the 4th quarter worth $2,356,000. Altium Capital Management LLC bought a new position in shares of Alpha Cognition during the 4th quarter valued at $1,620,000. Finally, Rosalind Advisors Inc. acquired a new position in Alpha Cognition during the fourth quarter worth $1,489,000.
Alpha Cognition Stock Performance
Shares of Alpha Cognition stock traded down $0.13 during trading on Tuesday, reaching $9.20. The company's stock had a trading volume of 22,621 shares, compared to its average volume of 97,819. Alpha Cognition Inc. has a one year low of $3.75 and a one year high of $11.40. The company has a market cap of $147.38 million, a price-to-earnings ratio of -7.67 and a beta of 2.78. The stock has a fifty day moving average price of $8.20.
Alpha Cognition (NASDAQ:ACOG - Get Free Report) last released its earnings results on Thursday, May 15th. The company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.58) by $0.38. The company had revenue of $2.93 million during the quarter, compared to the consensus estimate of $0.50 million.
Analyst Upgrades and Downgrades
ACOG has been the topic of a number of analyst reports. HC Wainwright reissued a "buy" rating and set a $20.00 price objective on shares of Alpha Cognition in a report on Friday, May 16th. Raymond James Financial upgraded shares of Alpha Cognition to a "moderate buy" rating in a research note on Tuesday, March 25th.
Check Out Our Latest Stock Report on ACOG
Alpha Cognition Company Profile
(
Free Report)
Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.
Read More
Before you consider Alpha Cognition, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alpha Cognition wasn't on the list.
While Alpha Cognition currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
